Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Q2 2025 Management View William J. Sibold, CEO, highlighted a "productive last few months" focused on driving the launch and building for the future, noting, "Rezdiffra’s quarterly run rate now ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for clinical trials in early 2026.

Marketing Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon By Ben Adams Nov 5, 2024 10:02am Madrigal Pharmaceuticals MASH GLP-1 Eli Lilly ...

Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their ...

In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million.

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA approvals.

The Mets signed Madrigal to a one-year deal back in January after he had been non-tendered by the Cubs. He’s never been much of a hitter, with just four home runs in 940 big league plate ...